Gilead Sciences, Inc. (FRA:GIS)
Germany · Delayed Price · Currency is EUR | Market Cap | 126.89B |
| Revenue (ttm) | 24.79B |
| Net Income (ttm) | 6.91B |
| Shares Out | n/a |
| EPS (ttm) | 5.47 |
| PE Ratio | 18.36 |
| Forward PE | 14.16 |
| Dividend | 2.82 (2.63%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 505 |
| Average Volume | 299 |
| Open | 103.04 |
| Previous Close | 107.00 |
| Day's Range | 102.14 - 103.04 |
| 52-Week Range | 82.00 - 111.04 |
| Beta | n/a |
| RSI | 48.34 |
| Earnings Date | Oct 30, 2025 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial numbers in USD Financial StatementsNews
AHF's Mobile Billboard Calls Out Gilead's Greed at Pharma Summit
LOS ANGELES--(BUSINESS WIRE)--As the pharmaceutical industry gathers for the Global Pharma & Biotech Summit in London this week, AIDS Healthcare Foundation (AHF) is launching a mobile billboard that w...
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
Gilead Sciences (GILD) Phase 3 Trial for Trodelvy Falls Short
Gilead Sciences (GILD) Phase 3 Trial for Trodelvy Falls Short
Gilead (GILD) Phase 3 Study Results for Trodelvy in Breast Cancer
Gilead (GILD) Phase 3 Study Results for Trodelvy in Breast Cancer
Gilead fails late-stage trial for Trodelvy in first-line breast cancer
Gilead's Trodelvy Misses Primary Endpoint In Phase 3 ASCENT-07 Breast Cancer Study
(RTTNews) - Gilead Sciences, Inc. (GILD) on Friday reported that the Phase 3 ASCENT-07 study, evaluating Trodelvy versus chemotherapy as a first-line treatment after endocrine therapy in HR+/HER2-nega...
Gilead's breast cancer drug fails to meet main goal of late-stage study
Gilead Sciences said on Friday its breast cancer drug Trodelvy failed to meet the main goal of a late-stage study.
Gilead Provides Update on Phase 3 ASCENT-07 Study
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a fir...
Gilead (GILD) Unveils Promising Long-term Data on Livdelzi for PBC
Gilead (GILD) Unveils Promising Long-term Data on Livdelzi for PBC
Gilead’s Livdelzi Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi (seladelpar) for people living with primary biliary cholangitis (PBC). F...
Gilead's Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living wi...
Interesting GILD Put And Call Options For December 26th
Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the December 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GI...
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: UBS Global Healthcare Con...
See Which Of The Latest 13F Filers Holds GILD
At Holdings Channel, we have reviewed the latest batch of the 34 most recent 13F filings for the 09/30/2025 reporting period, and noticed that Gilead Sciences Inc (Symbol: GILD) was held by 18 of thes...
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.
Fernandez: The market is on a high wire right now
Victoria Fernandez, Chief Market Strategist at Crossmark Global Investments, warns stretched valuations and rate concerns put markets on edge, calling Gilead a smart buy as biotech rebounds.
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of He...
Kalaris appoints Matthew Gall as CFO
Kalaris Therapeutics appoints Matthew Gall as CFO, bringing experience from iTeos, Sarepta, Celgene & Gilead.
Needham Reiterates Gilead Sciences (GILD) Buy Recommendation
Fintel reports that on October 31, 2025, Needham reiterated coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy recommendation. Analyst Price Forecast Suggests 8.29% Upside
GILD Stock: Wells Fargo Raises Price Target to $145, Maintains Overweight Rating | GILD Stock News
GILD Stock: Wells Fargo Raises Price Target to $145, Maintains Overweight Rating | GILD Stock News
JP Morgan Raises Gilead Sciences (GILD) Price Target to $150 | GILD Stock News
JP Morgan Raises Gilead Sciences (GILD) Price Target to $150 | GILD Stock News
Noteworthy Friday Option Activity: BX, SPOT, GILD
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Blackstone Inc (Symbol: BX), where a total of 16,715 contracts have traded so far, represen...
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Gilead Sciences Inc (NASDAQ: GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13 . GILD is in positive territory. Get the complete picture here The U.S. dr...